Will Healy

Will Healy

Will Healy is a freelance financial writer. He had a lifelong interest in the stock market, trading equities since the dot-com boom. Will pursued his passion for writing after working in the corporate world as both an analyst and an insurance sales professional. He likes to approach the market by focusing on deep value, dividends, and speculation.

Will’s writing has focused on stock analysis, as well as real estate, insurance, personal finance, macroeconomics, and politics. Along with InvestorPlace, his work has appeared on numerous sites, including Seeking Alpha, Yahoo! Finance, MSN Money, Kiplinger Tax Letter, and GOBankingRates. He holds both a B.S. in Journalism and an MBA in finance and strategy.

Recent Articles

As the Founders Depart, There’s a Real Opportunity in Alphabet Stock

With the company's founders stepping back, CEO Sindar Pichai could have more freedom to unlock some of the underlying value in Alphabet stock.

With No Revenue or Approved Treatments, Ocugen Stock Is a Clear Sell

How Ocugen stock came to be makes no sense. Neither does the idea that investors will continue to pour money into this cesspool.

Hurry Up and Wait for the Breakout in Bank of America Stock

With the Oracle of Omaha giving Bank of America stock its blessings, along with some positive economic signals, BAC appears a solid bet for the long haul.

Elon Musk’s Broken Promises Make Tesla Stock a Sell

Elon Musk brings both inventive genius and deep uncertainty to TSLA, and for this reason, investors should not pay a premium for Tesla stock.

Micron Stock Has Become a Tale of Two Opposing Influences

MU stock will probably struggle for now, but it could slowly turn around as negative influences give way to rising memory chip demand.

A Constellation Buyout Would Harm Canopy Growth Shareholders

Canopy Growth, like other marijuana stocks, continues trending downward. One big factor could prevent it from recovering.

Pinterest Stock Will Eventually Recover from Its Post-IPO Plunge

Like other social media stocks, PINS stock lost its post-IPO gains, but better monetization of its site should lead the way to recovery.

For Now, Amarin Stock Is a Gamble on FDA Approval

Although Amarin stock could potentially skyrocket off the pharmaceutical’s flagship drug Vascepa, approval challenges make this play incredibly risky.

Investors Should Buy Square Stock for Its Long-Term Potential

Square stock appears pricey and its competition continues to mount, But its ecosystem and foreign expansion should make SQ a winner.

Wait For News of a Signed Trade Deal Before Buying Alibaba Stock

Although Alibaba stock might tempt investors, the U.S.-China trade war has garnered a reputation for unpredictability. Therefore, it’s best to wait for a deal before diving in.